🇺🇸 Tenofovir alafenamide/emtricitabine in United States

32 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Virologic Failure — 6 reports (18.75%)
  2. Viral Load Increased — 5 reports (15.62%)
  3. Acute Kidney Injury — 4 reports (12.5%)
  4. Vomiting — 4 reports (12.5%)
  5. Drug Ineffective — 3 reports (9.38%)
  6. Anal Ulcer — 2 reports (6.25%)
  7. Bacteraemia — 2 reports (6.25%)
  8. Clostridium Difficile Colitis — 2 reports (6.25%)
  9. Cytomegalovirus Viraemia — 2 reports (6.25%)
  10. Diarrhoea — 2 reports (6.25%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Tenofovir alafenamide/emtricitabine approved in United States?

Tenofovir alafenamide/emtricitabine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tenofovir alafenamide/emtricitabine in United States?

ViiV Healthcare is the originator. The local marketing authorisation holder may differ — check the official source linked above.